The QualityStocks Daily Tuesday, December 17th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (NSPX) +78.57%

Penny Stock 101 (SKDI) +32.08%

RedChip (CTDH) +22.92%

The QualityStocks Daily Stock List

Apple Rush Company, Inc. (APRU)

Penny Stock Base, Wall Street Analyzer, MarketPlace.org, Financial Buzz, TipRanks, Market Wire News, Stockwatch, Research Pool, Wallet Investor, Stockhouse, MarketWatch, Morningstar, Barchart, Investing.com, OTC Markets, InvestorsHub, Investors Hangout, GlobeNewswire, and Simply Wall St reported earlier on Apple Rush Company, Inc. (APRU), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Apple Rush Company, Inc., through its subsidiary APRU, LLC, is a distributor of CPG (Consumer Packaged Goods )products under the trademarked Apple Rush brand and other labels. The Apple Rush brand has more than 40 years of existence in the natural beverage industry. The Company develops, bottles, markets, distributes, and sells varied beverages and snacks to wholesale and retail clients in the United States. Formed in 1998, Apple Rush Company lists on the OTC Markets.

Apple Rush Company offers organic sparkling juice blended beverages, with apple juice as the base under the brand name Apple Rush. The Company is an historical leader in the organic and natural beverage sector. Its objective is to also become the leader in the distribution of anhydrous hemp oil products throughout the nation.

Subsidiary APRU, LLC focuses on the development and sales of all natural Apple Rush sparkling juices, and research and development (R&D) of premium hemp extracts, which contain a broad spectrum of cannabinoids and natural hemp derivatives and other active ingredients including the Company’s exclusive agathos active, kratom, kava, blue lotus, and ginseng.

Apple Rush Company distributors that help distribute Apple Rush include Southern Eagle Distributing, Champagne Beverage, North Florida Sales, Grey Eagle Distributors & RJM Distributing. Apple Rush has brought on a group of advisors to help the Company gain National and International distribution. This group includes a number of leaders within the CPG (Consumer Packaged Goods) category and successful business executives.

The Apple Rush Company announced this month the hiring of Mr. Jason Atwell, former Chief Executive Officer of AAG-Live and Chief Operating Officer (COO) of Northern Holdings Farms and Ranches, to fill the position of COO. The Company also announced this month the addition of Mr. Randy Ornstein, former VP of Anheuser-Busch, to its official Advisory Board.

Mr. Tony Torgerud, Chief Executive Officer of Apple Rush Company, stated, “Apple Rush is building a world class team and we will be announcing additional advisors and business accomplishments regularly. We will be implementing several new shareholder programs, bringing our transparency to a new level. Stay tuned.”

Apple Rush Company, Inc. (APRU), closed Tuesday's trading session at $0.01175, off by 9.6154%, on 510,920 volume with 13 trades. The average volume for the last 3 months is 1,305,025 and the stock's 52-week low/high is $0.004699999/$0.024.

Basic Energy Services, Inc. (BASX)

Zacks, OTC Markets, Street Insider, InvestorsHub, Seeking Alpha, Morningstar, Barchart, MarketWatch and PR Newswire reported previously on Basic Energy Services, Inc. (BASX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the USA. The Company supports six geographic markets conducting operations in the Texas Gulf Coast region, the Central region, the Permian Basin of West Texas, California and the Rocky Mountains. Its services include Well Servicing, Midstream Services, Water Logistics, Pumping Services, and Rental/Fishing Tools. Basic Energy Services is based in Fort Worth, Texas. The Company lists on the OTC Markets Group’s OTCQX.

Basic Energy Services provides its services to a varied group of more than 2,000 oil and gas companies. The Company’s operations are centered in liquids-rich basins, which have historically exhibited strong drilling and production economics in recent years with a considerable presence in the Permian Basin, Powder River Basin, and the Bakken, Eagle Ford, and Denver-Julesburg shales.

Basic's Well Servicing operations take advantage of a modern fleet of high spec workover rigs, 24 hour rig packages and 700 rig series, matched to the needs of the local markets. Its high spec well servicing rigs perform reliable services to maintain and improve production throughout the productive life of the well. The Company’s Water Logistics operations provides oilfield fluid supply, transportation, storage and disposal services required in workover, completion and remedial projects and also in daily producing well operations.

Basic Energy Services’ Pumping Services include Hydraulic Fracturing; Cementing; Acidizing; Nitrogen; Coil Tubing; Water Solution Services; and Frac Stacs. Moreover, the Company’s Midstream Services is now Agua Libre Midstream. Basic also has its network of 24 Rental & Fishing Tools facilities. The Company offers a wide-ranging line-up of rental tools that range from the smallest to the largest and also an extensive inventory of fishing tools.

Last week, Basic Energy Services announced a plan to divest of its pumping services assets (not inclusive of coiled tubing) in numerous transactions with expected proceeds of roughly $30 to $45 million. The divestiture is designed to bolster Basic’s core remaining production-focused businesses of well servicing and water logistics. In addition, this non-core divestiture will fund the projected 2020 and 2021 capital budget of Agua Libre Midstream, the Company’s fast growing, high return-on-assets business.

Basic Energy Services, Inc. (BASX), closed Tuesday's trading session at $0.2303, up 0.567686%, on 519,162 volume with 164 trades. The average volume for the last 3 months is 544,446 and the stock's 52-week low/high is $0.150999993/$6.28999996.

Interlink Electronics, Inc. (LINK)

MacroTrends, Market Screener, Whale Wisdom. GlobeNewswire, Street Insider, AI Stock Finder, Investing. Com, Stockhouse, Last10k, Simply Wall St, Dividend Investor, TMXmoney, GuruFocus, MarketBeat, Stockopedia, Market Exclusive, and InvestorsHub reported beforehand on Interlink Electronics, Inc. (LINK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Interlink Electronics, Inc. is a world-leading trusted advisor and technology partner in the advancing world of human-machine interface (HMI) and force-sensing technologies. The Company has led the printed electronics industry in its commercialization of its patented Force-Sensing Resistor (FSR®) technology, which has enabled strong and reliable HMI solutions. Established in 1985, Interlink Electronics is based in Camarillo, California.

The Company’s products include Force Sensing Resistor® technology, Force sensing linear potentiometers (FSLP), and integrated mouse modules & pointing solutions. Interlink Electronics was founded on the invention and commercialization of the Force Sensing Resistor®. As the Company transitions from an FSR® sensor supplier to an HMI solution provider, it is pursuing and embracing cutting-edge sensor technology platforms. It is working to advance the HMI and Force-Sensing Technology Revolution™.

Interlink Electronics also serves its customer base from its worldwide research and development (R&D) center in Singapore, its printed-electronics manufacturing facility in Shenzhen, China, and its global distribution and logistics center in Hong Kong. Additionally, it maintains technical and sales offices in Japan and at different locations in the U.S.

Interlink delivers multi-platform sensor solutions to the world's major OEMs (Original Equipment Manufacturers), Tiers and Integrators. Its solutions focus on handheld user input, menu navigation, cursor control, and other intuitive interface technologies for the world's leading electronics manufacturers.

Interlink Electronics has a proven track record of supplying HMI solutions for mission-critical applications in a broad variety of markets. These include, but are not limited to, consumer electronics, automotive, industrial, and medical devices. The Company’s product development teams skilled capabilities are in concept definition, rapid prototyping, hardware and firmware development and integration support.

In November, Interlink Electronics announced the launch of its next generation of rugged sensors and solutions—the FSR X™, FSR UX™, and VersaPad Plus™. The FSR X and FSR UX are the newest models in the Company’s line of Force Sensing Resistors® (FSR) - technology that Interlink pioneered almost 35 years ago—and offer more precision, enhanced stability, as well as easy integration. The VersaPad Plus is the latest and largest incarnation of the ultra-tough, all-weather VersaPad, the touchpad of choice for the globe’s foremost rugged laptop producers.

Mr. Steven N. Bronson, President and Chief Executive Officer of Interlink Electronics, said, "For decades, we have stood at the forefront of the printed electronics and HMI markets, and now we are looking toward a future where people will be relying on our sensors more than ever before thanks in large part to the rise of the IoT. It's inspiring to help lead the market sector during this disruptive paradigm shift."

Interlink Electronics, Inc. (LINK), closed Tuesday's trading session at $5.55, off by 7.50%, on 400 volume with 4 trades. The average volume for the last 3 months is 6,090 and the stock's 52-week low/high is $1.62/$8.60000038.

NameSilo Technologies Corp. (URLOF)

All Penny Stocks, Stockwatch, Market Wire News, InvestorX, Investors Hangout, Wallet Investor, Stockhouse, Nasdaq, Market Screener, Dividend.com, TradingView, Barchart, Dividend Investor, GuruFocus, Morningstar, MarketWatch and Seeking Alpha reported beforehand on NameSilo Technologies Corp. (URLOF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

NameSilo Technologies Corp. is one of the fastest growing domain registrars in the world. Its subsidiary, NameSilo LLC, is a low-cost provider of domain name registration and management services. As an accredited ICANN registrar, NameSilo has roughly 3.4 million active domains under management, and greater than 310,000 customers from approximately 160 countries.

The Company previously went by the name Brisio Innovations, Inc. It changed its corporate name to NameSilo Technologies Corp. in December of 2018. NameSilo Technologies is based in Vancouver, British Columbia. The Company lists on the OTC Markets.

NameSilo Technologies invests its capital in companies and opportunities that Company Management believes are undervalued and that have the potential for considerable appreciation. NameSilo Technologies makes investments in public and private markets and centers on opportunities in a broad array of industries excluding the resource and resource service sectors.

Last week, NameSilo Technologies announced it has partnered with the cloud brokerage platform NuSEC to offer a new domain name resolution service, which resolves its customer's DNS requests via a global network of redundant DNS servers for a safer, smarter and faster Internet experience. Last month, it was reported that Google will be identifying and labelling slow performing websites.

The new Premium DNS Service is called "NuDNS". It will permit NameSilo customers to accelerate the resolution of their websites, and simultaneously minimize the risk of a DDOS attack. NuSEC is a worldwide platform. It is built purposely for the hosting and domain name industry, with full white label capability and is localized for partners' languages and currencies. The NuSEC platform gives access to a set of products that will channel SMB Web Presence spend back through the hosting community.

Kristaps Ronka, Chief Executive Officer at NameSilo, stated "We love the NuSEC platform and their DNS product was the obvious entry point for us to integrate into the platform. Now we can offer multiple product lines from this single point of integration. Security is incredibly important to us and our customers, and when we saw the news that Google was about to start publishing slow loading websites, we knew we had to prioritize this project.”

NameSilo Technologies Corp. (URLOF), closed Tuesday's trading session at $0.414, up 5.424%, on 46,000 volume with 3 trades. The average volume for the last 3 months is 53,186 and the stock's 52-week low/high is $0.244699999/$0.414000004.

Orex Minerals, Inc. (ORMNF)

Stockhouse, Stock Scores, Broker Newswire, Smart Stock Trading Strategies, Lamp News, Mining Capital, Mining Stock Education, 4-Traders, Finance Recorder, Gold Stock Data, Macroaxis, Dividend Investor, TradingView, PR Newswire, Mining Stock Valuator, Barchart, GuruFocus, OTC.watch, Seeking Alpha, Morningstar, Mexico Mining Center, Nasdaq, Wallet Investor, Junior Mining Network, MarketWatch and Market Screener reported earlier on Orex Minerals, Inc. (ORMNF), and today we are highlighting the Company, here at the Quality Stocks Daily Newsletter.

Orex Minerals, Inc. is a junior mineral exploration company based in Vancouver, British Columbia. It has a portfolio of large gold, silver, and copper exploration projects on well-known mineral trends in Mexico (Coneto, San Luis del Cordero and Sandra Escobar Projects), and Canada (Jumping Josephine Gold Project). The Company is under the management provided by the experienced Belcarra Group Management Ltd. The Belcarra Group consists of highly qualified mining professionals. Orex Minerals lists on the OTC Markets Group’s OTCQB.

Three of the Company’s projects are in Durango State, Mexico. These include the Coneto Silver-Gold Project as a joint venture (JV) with Fresnillo PLC; the Sandra Escobar Silver Project with Pan American Silver Corp.; and the San Luis del Cordero Silver-Copper-Zinc Project. Orex's fourth project is the Jumping Josephine Gold Project in the Province of British Columbia, Canada.

The Coneto Silver-Gold Project is in the Mesa Central, on the eastern flank of the Sierra Madre Occidental Mountains. It is in the region around the village of Coneto de Comonfort, 100 km north of Durango City, in Durango, Mexico. At Coneto, Orex Minerals has 45 percent ownership of 4,995 hectares of mineral concessions.

The Sandra Escobar Project is a silver and gold exploration property. It is 40 km north of the community of Tepehuanes and 180 km north of the City of Durango in Durango State, Mexico. The project comprises the Sandra Property of 6,335 hectares and the Escobar Property of 635 hectares of mineral concessions.

The San Luis del Cordero Silver-Copper-Zinc Project is a skarn and epithermal vein hosted silver-copper-zinc district, situated 155 kms NNE of the City of Durango and immediately north of the town of San Luis del Cordero. Old mine workings and mineralized showings wrap around a quartz-feldspar-porphyry intrusive. The mineral concessions total 2,825 hectares.

The Jumping Josephine Gold Project is in the West Kootenay Region in southern British Columbia. It consists of 24 current mineral claims totalling 11,667 hectares. The property includes the historic Granville Mountain Mining Camp.

Last month, Orex Minerals announced that it completed a private placement financing to raise gross proceeds of $800,000 from the sale of 8,000,000 units at a price of $0.10 per unit, with each unit consisting of one common share and one-half of one warrant. The Company intends to use the net proceeds of the Offering to maintain its 40 percent share of the Sandra-Escobar Project in good standing and fund its 40 percent share of the forthcoming work program. It also intends to use the net proceeds of the Offering to make the necessary payments under its existing option to acquire 100 percent of the Cordero Project and for general corporate and working capital purposes.

Orex Minerals, Inc. (ORMNF), closed Tuesday's trading session at $0.0558, up 0.359712%, on 22,900 volume with 2 trades. The average volume for the last 3 months is 6,523 and the stock's 52-week low/high is $0.032000001/$0.093299999.

TearLab Corporation (TEAR)

Zacks, MacroTrends, Wallet Investor, TipRanks, Simply Wall St, MarketBeat, Nasdaq, Market Screener, GlobeNewswire, StockInvest.us, Investing.com, Morningstar, BioSpace, TMXmoney, and Simply Wall St reported previously on TearLab Corporation (TEAR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

TearLab Corporation develops and markets lab-on-a-chip technologies. These technologies enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The OTCQB-listed Company’s mission is to pioneer the future of tear film diagnostics to elevate patient care. TearLab has its corporate office in Escondido, California.

The TearLab Osmolarity Test is for diagnosing Dry Eye Disease. It is the first assay developed for the award-winning TearLab Osmolarity System. The TearLab Osmolarity System is a proprietary in vitro diagnostic tear testing platform. It measures tear film osmolarity for the diagnosis of dry eye disease. In addition, it enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.

The Company’s TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. TearLab is for professional in vitro diagnostic use only.

Recently, TearLab reported its consolidated financial results for Q3 ended September 30, 2019. The Company’s Net Revenues were $5.6 million, down 8.5 percent from $6.2 million for the same period in 2018. TearLab’s reported Net Loss for the 2019 Q3 was roughly $1.8 million, or ($0.14) basic loss per share, versus a reported Net Loss of roughly $0.2 million, or ($0.02) basic loss per share in Q3 of 2018.

The Company expanded the U.S. active device base to 4,831 and active accounts to 1,837 TearLab Osmolarity Systems. Seph Jensen, TearLab’s Chief Executive Officer, said, “We remain committed to growing osmolarity through the continued expansion of our customer base and are focused on securing FDA clearance of our next-generation TearLab Discovery™ System.”

TearLab Corporation (TEAR), closed Tuesday's trading session at $0.052, up 4.7331%, on 44,709 volume with 10 trades. The average volume for the last 3 months is 27,189 and the stock's 52-week low/high is $0.029999999/$0.150000005.

Trucept, Inc. (TREP)

Pennystocks.news, OTC Dynamics, Contexxia, Stock News Now, Stockhouse, TipRanks, Stockopedia, Market Screener, GuruFocus, StockPulse, Infront Analytics, Business Insider, InvestorsHub, Investing Online, PR Newswire, and Biz Journals reported beforehand on Trucept, Inc. (TREP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Trucept, Inc. is a foremost consulting and service provider to the Professional Employer Organization and Consumer Goods industries. By way of its subsidiaries, it provides professional employer organization staffing and business processing services to small and medium-size businesses in the United States. The Company previously went by the name Smart-Tek Solutions, Inc. It changed its name to Trucept, Inc. in January 2013. Established in 1995, Trucept has its head office in San Diego, California. The Company lists on the OTC Markets.

Trucept’s services enable customers to outsource human resources tasks. This includes payroll processing, workers' compensation insurance, health insurance, employee benefits, 401k investment services, personal financial management, and income tax consultation principally related to staffing comprising staff leasing, temporary staffing, and co-employment. In addition, the Company provides healthcare staffing services.

This past June, Trucept announced the expansion of its Strategic Marketing and Technology products and services by appointing Mr. Fawad Nisar as Executive Vice President for its new wholly-owned subsidiary, Trucept Marketing, Inc. Mr. Nisar spent 13 years at Trellist Marketing & Technology, providing business consulting, brand and marketing strategy, and technology expertise to Fortune 500 enterprise clients in healthcare, pharmaceuticals, retail, manufacturing, and financial industries.

Furthermore, he brings valuable expertise within the cannabis industry, especially in product development, and sales & marketing of cannabidiol (CBD). Trucept will assist marketing partners with a CBD line to wholesalers and distributors, with a processing and production capacity of 52kg of pure CBD oil per week.

Yesterday, Trucept announced it is expanding its human resources (HR) support to clients with the addition of Dr. Karen Pence. Dr. Pence has greater than 25 years of progressive HR experience working for small and large companies in diverse industries in Southern California. Most recently, she worked for six years with Employers Resource, a PEO/ASO company in San Marcos, as HR Director. She is an adjunct professor at University of Redlands and University of California, Riverside, teaching SHRM certification classes of other HR professionals. Dr. Pence is SHRM-SCP certified as well as HRCI SPHR-CA certified.

Trucept, Inc. (TREP), closed Tuesday's trading session at $0.0132, off by 6.383%, on 26,966 volume with 3 trades. The average volume for the last 3 months is 28,309 and the stock's 52-week low/high is $0.009999999/$0.097000002.

STR Holdings, Inc. (STRI)

Zacks, Street Insider, GlobeNewswire, StockInvest, 4-Traders, Real Investment Advice, Capital Cube, and Wallet Investor reported beforehand on STR Holdings, Inc. (STRI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

STR Holdings, Inc. is a worldwide provider of high quality, superior performance encapsulants for the photovoltaic (PV) module industry. It pioneered the solar encapsulant market over three decades ago with the invention of EVA encapsulant. STR Holdings, Inc. is a subsidiary of Zhen Fa New Energy (U.S.) Co., Ltd. Established in 1944, STR Holdings has its head office in Enfield, Connecticut. The Company has manufacturing locations in the U.S, Spain, and Malaysia.

STR Holdings designs, develops, and manufactures encapsulants, which protect the embedded semiconductor circuits of solar panels for sale to solar module manufacturers. The Company also designs, develops, and manufactures multi-layer films for packaging applications, such as meat, fish, cheese, yogurt, fruit, cereals, snack foods, and more. STR’s encapsulants can be used in crystalline silicon and thin-film solar modules.

Ethylene Vinyl Acetate (EVA) has been the chief material used in solar encapsulants for the last few decades. STR PHOTOCAP® EVA is the only encapsulant technology with a proven track record of maintaining durability, adhesion, stability and transparency after greater than 30 years of field exposure. STR works directly with its customers to improve their lamination processes and subsequently, improve the quality of their modules, increase yield and lessen costs.

More than 20 Gigawatts of STR Protected™ Modules are in the field. Encapsulant reliability necessitates accurate, repeatable formulation, premier quality raw materials and strict process control. First-rate long-term optical performance of STR Encapsulant facilitates maximum power output. STR Encapsulant touches every component of the solar module. Therefore, it must be chemically and physically compatible to enhance module durability.

STR Protected includes user-friendly no shrink technology during the manufacturing of its encapsulant. This means zero shrink and no adverse impact on adhesion to glass, cell or backsheet, which can harm modules in the field.

STR Holdings has its PHOTOCAP® encapsulant. The Company’s products range from its traditional standard and fast cure grades to industry leading ultra-fast and mega-fast cure encapsulants to optimize module production throughput. Products include PHOTOCAP® 15580P for use in front or in back of cells, and PHOTOCAP® 15585P HLT™ for use in front of cells. PHOTOCAP® products also include PHOTOCAP® 15585S HLT™ for use in front of cells; PHOTOCAP® 35530P - ultra-fast cure kinetics; and PHOTOCAP® 35521P HLT™ - ultra-fast cure kinetics.

STR Holdings, Inc. (STRI), closed Tuesday's trading session at $0.13, up 36.8421%, on 102,714 volume with 11 trades. The average volume for the last 3 months is 11,926 and the stock's 52-week low/high is $0.07/$0.388000011.

Medifocus, Inc. (MDFZF)

MoneyHub, OTC Markets, Wallet Investor, SmallCapVoice, Investor Place, Investor Network, Barchart, Street Insider, Financial Content, Trading View, MarketWatch, and otc.Watch reported beforehand on Medifocus, Inc. (MDFZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifocus, Inc. has a portfolio of medical technologies that use patented  Focal Thermal Technology  to treat conditions ranging from Prostate Diseases to Breast Cancer. The Company’s portfolio of medical products includes thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer. OTCQB-listed, Medifocus is based in Columbia, Maryland.

The Company owns two technology platforms with approximately 100 issued and pending U.S. and worldwide patents. One platform is the “Endo-thermotherapy Platform”. The other platform is the “Adaptive Phased Array Microwave Focusing Platform”.

Based on these proprietary technology platforms, Medifocus has developed two advanced therapeutic products. One is the Prolieve® system for the treatment of BPH. The other is the Adaptive Phased Array (APA)-1000 system for the treatment of breast cancer.

The Prolieve® Thermodilatation™ System provides symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) via a simple, 45-minute, in-office treatment. Prolieve® is Food and Drug Administration (FDA) and Medicare approved for treating symptomatic BPH with more than 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy, and durability. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy, and also certain types of surgical procedures to treat the symptoms of BPH.

Medifocus’ Heat Activated Gene Therapy, exclusively licensed from Duke University, aims at using the Company’s Focal Thermal Technology to enhance selective expression of therapeutic genes injected intratumorally to optimize cancer cell killing while lessening systemic side effects.

The APA 1000 Breast Cancer Treatment System developed by the Massachusetts Institute of Technology (MIT) has been shown in Phase 2 clinical trials to offer substantial additional shrinkage of the sizes of breast cancer in combined ChemoThermal therapy versus Chemotherapy alone. Additionally, it was shown to be effective in reducing margin positivity when patients were treated with APA 1000 before lumpectomy.

Recently, Medifocus announced that its Prolieve® Thermodilatation™ procedure for the treatment of BPH have been performed and reimbursed by insurance carriers in Hong Kong.

Dr. William Jow, said, “We are pleased that our efforts, together with the contribution from our Asian partners, are starting to yield tangible financial results from Prolieve® sales. Through our resolution in promoting Prolieve® in Asia and after having presented at three major international conferences within the past 16 months, I would like to see Prolieve® sales start to pick up in the near future both domestically and internationally. We are pleased to enter the fast-growing Asia markets where BPH and cancers of the prostate and breast are quickly becoming major public health concerns.”

Medifocus, Inc. (MDFZF), closed Tuesday's trading session at $0.0038, up 90.00%, on 100,000 volume with 1 trade. The average volume for the last 3 months is 8,232 and the stock's 52-week low/high is $0.001099999/$0.030999999.

Creative Medical Technology Holdings, Inc. (CELZ)

Live Trading News, MarketWatch, Emerging Growth, Stockhouse, Bio Quick News, Capital Cube, OTC Markets, InvestorsHub, Canadian Insider, and 4-Traders reported earlier on Creative Medical Technology Holdings, Inc. (CELZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company listed on the OTC Markets Group’s OTCQB. The Company’s focus is on Urology and Neurology using stem cell treatments. Since 2011, CMT and its affiliate company, Creative Medical Health, Inc., have concentrated on regenerative medical solutions for unmet Urological and Neurological needs.  The Company has a patent portfolio that encompasses all treatments.  CMT has its corporate office in Phoenix, Arizona.

The Company has formed CaverStem International LLC. This is a majority-owned subsidiary centered on commercializing stem cell therapy for erectile dysfunction to global physicians and their patients. CaverStem is offering the Caverstem™ technology to selected physicians in the United States that qualify according to CMT's criteria.

CMT has also established CerebroStem LLC. This majority-owned subsidiary focuses on developing stem cell therapies for brain injuries and neurodegenerative diseases. Its initial focus will be treating radiation induced brain damage.

Via its own research and collaborations with top academic institutions, CMT has acquired a pioneering stem cell (AmnioStem) and developed proprietary protocols. Moreover, the Company has built an extensive intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA.  CMT is also making advances for treating stroke using its newly acquired amniotic fluid-based stem cell. 

AmnioStem is Amniotic fluid derived stem cell. The AmnioStem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable way. AmnioStem cells do not necessitate matching with the recipient, as one size fits all.

Recently, CMT  announced an update of its activities. Regarding CaverStem domestic activities, the Company is continuing marketing to physicians throughout the U.S. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and growing each month. CMT anticipates reaching financial self-sufficiency by revenues from sales this year.

Creative Medical Technology Holdings, Inc. (CELZ), closed Tuesday's trading session at $0.00025, up 25.00%, on 5,172,637 volume with 15 trades. The average volume for the last 3 months is 36,803,505 and the stock's 52-week low/high is $0.000099999/$0.015499999.

DynaResource, Inc. (DYNR)

Simply Wall St, Stockhouse, Real Investment Advice, The Street, Morningstar, 4-Traders, Barchart, Vantage Wire, Stockwatch, WSIC News, Market Exclusive, Proactive Investors, Marketbeat, Marketwired, Dividend Investor, InvestorsHub, Wallet Investor, Market Screener, MarketWatch, OTC Markets, Investor Place, GuruFocus, and Capital Cube reported on DynaResource, Inc. (DYNR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

DynaResource, Inc. is a Junior Resource Company based in Irving, Texas. It holds 80 percent of the outstanding shares of DynaResource de Mexico, S.A. de C.V., (DynaMexico). DynaMexico owns 100 percent of the mineral concessions and related interest to the San Jose de Gracia District (SJG). This encompasses roughly 69,133 hectares in Northern Sinaloa, Mexico. DynaResource’s shares trade on the OTC Markets Group’s OTCQB.

DynaUSA currently holds 80 percent of the total outstanding Capital of DynaMexico. DynaUSA presently holds 100 percent of DynaMineras.

The SJG is a 15 square kilometers mineralized area. It has historic production of 1 M Oz. Gold, bonanza grades. The Metallurgy Program is completed. It confirmed 95 percent recoveries in metallurgical testing and in pilot production operation. The SJG Property presently contains the potential for hosting a greater than 3,000,000 Oz. AU resource.

DynaResource focused its efforts in mid 2006 on the financing, exploration, and development of SJG. At September 1, 2006, it signed a definitive agreement with Goldgroup Mining, Inc., to provide for an $18 million financing of exploration and development activities at the SJG. At March 15, 2011, Goldgroup had contributed the $18M.

For the SJG Project, a Surface Rights Agreement is completed. There is confirmation of major vein deposits; with bonanza grades. In addition, there is location of bulk tonnage potential at Palos Chinos; (15 meters @ 3 grams/ton; 7m @ 7 grams/ton).

The SJG Project had 4,750 oz. gold produced at the San Pablo Area in 5 months production, 2003. It had an Average Grade of 25 G/T; 90% Recoveries. It had greater than 18,250 oz. gold produced through June 30, 2006. Overall Average Grade was approximately 20 G/T. Average Production Cost was approximately $175/oz. It transitioned from Pilot Production to Exploration in 2006 to concentrate on drilling and definition of resources.

DynaResource, Inc. and DynaResource De Mexico SA De C.V. announced in February 2018 a favorable decision from a US District Court Magistrate Judge recommending the vacating of a 2016 arbitration award. DynaResource (DynaUSA) and its affiliate DynaResource de Mexico SA de C.V. (DynaMexico), the 100 percent owner of the San José de Gracia Project in Sinaloa, México (collectively DynaResource), announced that a previous attempt by Goldgroup Resources, Inc. to confirm an international arbitration award adverse to DynaResource was rejected by a United States District Court.

DynaResource, Inc. (DYNR), closed Tuesday's trading session at $0.5998, up 53.7949%, on 100 volume with 1 trade. The average volume for the last 3 months is 3,370 and the stock's 52-week low/high is $0.239999994/$1.22000002.

Airborne Wireless Network (ABWN)

Epic Stock Picks, PennyStockLocks.com, Penny Stock 101, StockRockandRoll, Penny Stock Craze, Penny Stocks Finder, OTCBB Journal, Stock Commander, Profitable Trader Authority, Damn Good Penny Picks, Penny Picks, Beacon Equity Research, Broad Street, and SuperStockTips reported earlier on Airborne Wireless Network (ABWN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Airborne Wireless Network’s mission is to be a high-speed broadband internet pipeline to improve coverage connectivity now lacking. Its intention is  to create a high-speed broadband airborne wireless network through linking commercial aircraft in flight. Each aircraft participating in the network will act as an airborne repeater or router, sending and receiving broadband signals from one aircraft to the next. This will create a digital superhighway in the sky. Airborne Wireless Network has its head office in Simi Valley, California.

Airborne Wireless Network has completed its acquisition of Patent Number US 6,285,878 B1 and the Trademark "Infinitus Super Highway". These acquired assets serve as a blueprint and road map for it to develop its "Airborne Wireless Network”.

Concerning its Wholesale Carrier Network, the Company’s plan is to use commercial aircraft as “mini-satellites”. Its primary target customer-base will be international data and communications service providers.  Airborne Wireless Network’s system is to operate in a safe and controlled environment, usually between 20,000 and 40,000 feet (6,000-12,000 m).

The Company is developing a completely meshed network. In a completely meshed network, signals come in from numerous directions. The system will route signals around any obstructions. Fundamentally, it is a virtual airborne Worldwide Web. Because it is a meshed network, it is comparable to a web where all nodes are connected through many links.

Airborne Wireless Network  will act as a wholesale carrier with target customers. The Company believes that its network, upon development, should provide low cost, high-speed connectivity to rural areas, island nations, ships at sea, oil platforms, in addition to connectivity to commercial and private aircraft in flight.  

In January of this year, Airborne Wireless Network announced that on December 26, 2017, it entered into a service agreement with iNTELLICOM Technologies, Inc. to support the development and advancement of its Infinitus Super Highway™.

This past March, Airborne Wireless Network announced that on March 6, 2018 it entered into an Agreement with South Bay Aviation (Torrance, California based), for two airplanes for the upcoming second flight test of the Infinitus Super Highway network. The Company looks to expand on its initial RF proof of concept test that was completed in May 2017 using two Boeing 767-300ER aircraft and a mobile mast imitating a ground station.

Also in March, Airborne Wireless Network announced that on March 26, 2018 it applied with the FAA (Federal Aviation Administration) for experimental operating certificates for each flight test demonstration aircraft. Upon approval, these applications will allow for the modification and installation of the Infinitus Superhighway RF and Optical components on each of the two Cessna aircraft Airborne Wireless Network has arranged for use in connection with its upcoming demonstration tests of Infinitus.

Airborne Wireless Network (ABWN), closed Tuesday's trading session at $0.0001, up 9,900.00%, on 3,620,438 volume with 9 trades. The average volume for the last 3 months is 2,920,632 and the stock's 52-week low/high is $0.000000999/$0.000199999.

Prism Technologies Group, Inc. (PRZM)

Zacks, Wall Street Journal, TradingView, MarketWatch, and InvestorsHub reported on Prism Technologies Group, Inc. (PRZM), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Prism Technologies Group, Inc. is an intellectual property (IP) licensing and technology research & development  (R&D)  company. The Company, by way of its wholly-owned subsidiaries, owns a patent portfolio consisting of nine patent families incorporating 61 issued and six pending patents in the Computer & Network Security, Semiconductors, and Medical Technology arena.

Established in 1995, Prism Technologies Group is the parent company of Prism Technologies, LLC, which is a Nebraska Limited Liability Company (LLC) based in Omaha, Nebraska. Prism Technologies Group has its corporate office in Folsom, California.

The Company previously went by the name Internet Patents Corporation. It changed its name to Prism Technologies Group, Inc. in September of 2015. The Company lists on the OTC Markets Group’s OTCQB.

Prism Technologies Group licenses and enforces a portfolio of patents relating to its technologies. It continues to develop and patent new technologies.

The Company’s dedication is to continuing R&D efforts in a number of fields. Its mission is to continue to develop and invent new technologies in computer and network security, wearable computing, transaction processing,  and healthcare to speed up time to market opportunities for its clients.

Prism Technologies Group’s Executive Team includes Mr. Hussein A. Enan - Chairman, Chief Executive Officer; and Mr. Greg Duman - President, Prism Technologies, LLC and member of Prism Group's Board of Directors. Mr. Duman chairs the Audit Committee. Prism Technologies Group announced in October of 2017 that it entered into an Asset Purchase Agreement with Amorphous Technologies International (ATI). ATI is a leader in the development of innovative amorphous alloy solutions based on proprietary materials technology. Its solutions deliver value through removing the limits of existing materials technology, which result in high costs throughout the lifecycle of a product.

The Agreement is to acquire certain intellectual property (IP) assets related to unique uses for amorphous metals.  After the close of the transaction, Prism will commercialize the acquired IP assets to create new amorphous metal technology offerings for the consumer electronics, automotive, industrial, and other business sectors.

Prism Technologies Group, Inc. (PRZM), closed Tuesday's trading session at $0.0255, up 42.2991%, on 14,351 volume with 2 trades. The average volume for the last 3 months is 2,639 and the stock's 52-week low/high is $0.0151/$0.140499994.

Inspyr Therapeutics, Inc. (NSPX)

TheMicrocapNews, TaglichBrothers, Stock News Now, SmallCapVoice, Marketbeat.com, and OTC Markets Group reported earlier on Inspyr Therapeutics, Inc. (NSPX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company based in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients’ with numerous different tumor types. Inspyr Therapeutics’ team has considerable pharmaceutical industry and scientific experience.

The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name GenSpera, Inc. It changed its name to Inspyr Therapeutics, Inc. in August of 2016.  

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.  

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). In addition, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.  

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program centers on the treatment of gastric cancer.

Inspyr has started a preclinical study in gastric cancer PDX tumor models that express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.   

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. This unique platform technology has the potential to work across a range of drugs that precisely target different cancers.  

In October of 2017, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics, Inc.  (NSPX), closed Tuesday's trading session at $0.01, up 78.5714%, on 861,500 volume with 37 trades. The average volume for the last 3 months is 194,477 and the stock's 52-week low/high is $0.005599999/$0.326249986.

The QualityStocks Company Corner

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF)

The QualityStocks Daily Newsletter would like to spotlight Wonderfilm Media Corporation (OTC: WDRFF).

Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), a leading entertainment company producing internationally appealing, high-quality feature films and episodic television, is working on quality theatrical releases and entertainment content to meet the fast-growing global demand for content caused by the unprecedented expansion of streaming services.

Wonderfilm Media Corporation (TSXV: WNDR) (OTC: WDRFF) main business is the worldwide production of high-quality feature films and episodic television. The Wonder?lm team includes Hollywood veterans who have packaged, produced and delivered several profitable recent films, including “BlacKkKlansman,” “Get Out” and “The Hurt Locker.” Having these individuals on the Wonderfilm team demonstrates the company’s proven access to Academy Award-quality films and upside.

Wonder?lm maintains a continuing $58 million annual production slate to meet the constant and growing need for content worldwide. The company’s risk-averse production process results in predictable and consistent revenue streams.

Soaring demand for content from streaming providers is fueling industry growth. The global media and entertainment market is expected to grow from $1.9 trillion in 2017 to $2.4 trillion in 2022, a five-year CAGR of 4.4%.

The company recently formed Wonderfilm Global, an international film and television sales and distribution joint venture that is expected to generate significant incremental revenue.

Wonderfilm has strong relationships throughout the entertainment industry, which enables cost-effective production budgets and in-demand content creation.

Management Team with Proven Track Records

Kirk Shaw: Over 240 movies and seven television series to his credit. Headed up Canada’s largest independent film and television production company, attaining $100 million revenue two years straight with 8% EBITDA.

Dan Grodnik: Founded Mass Hysteria Entertainment, a publicly traded company, and became its chairman/CEO. Produced over 50 feature films, including “Bobby,” the 2006 Robert Kennedy biographic film.

Shaun Redick & Yvette Yates: $300 million+ USD total production budgets to date with a combined 175 award wins/355 nominations, including 10 Oscar nominations. In 2017 and 2018, they produced two of the most successful Hollywood films of those years: “Get Out” ($255 million USD gross revenue) and “BlacKkKlansman” ($100 million USD gross revenue). Scheduled to produce two to three films per year for Wonderfilm, with the first release slated for October 2020. Committed to the 4% challenge to give more women and women of color the opportunity to direct.

Jeff Bowler: 2017 Emmy Award-winning producer. Vice president of acquisitions and production for The Exchange, one of the top film sales and finance companies in the world. Bowler is the executive for Wonderfilm Global distribution.

Bret Saxon: Through his company, TMP Inc., Saxon created M&A deals worth over US$750 million across 113 countries. Produced several feature films and made-for-television movies, including Wonderfilm’s 2019 movie “Zombie Tidal Wave” for NBC/Universal’s SYFY.

17-Title Movie Slate — Greenlit

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few.

Some of the company’s most notable greenlit projects include the horror film “Amityville 1974,” slated for theatrical release in October 2020, and the action film “Inside Game” starring Tyrese Gibson, which will be released to theaters in fall 2020.

The company is also actively developing a number of other new IP projects, including a dramatic biographic feature titled “Life and Times of Steve McQueen,” a film adaptation of the bestselling novel “Merchant of Death” and a television series headed by “CSI: Crime Scene Investigation” creator Anthony Zuiker.

 

Potential for Breakout Success

Wonderfilm movies have the potential for millions of dollars in revenue from the kind of breakout success generated by films like “Saw” and “Get Out,” which would propel Wonderfilm and its revenue streams to a new level. Wonderfilm has several potential breakout films in its development/production queue.

Note: Potential breakout films are not factored into company’s revenue projections.

Base Hits and Home Runs

In tandem with its slate of high-profile films, Wonder?lm continues to finance, produce and deliver many profitable low-risk, lower-budget films that are base hits. Shaun Redick is a home run hitter, and his upcoming Wonderfilm projects are anticipated to be home run hits for the company, while base hits such as “Zombie Tidal Wave” provide a consistent source of revenue.

Recent Industry Breakout Films Include:

  • SAW – $1.2 million budget = $103.9 million in sales
  • Pulp Fiction – $8 million budget = $212 million in sales
  • My Big Fat Greek Wedding – $5 million budget = $250 million in sales
  • Lost in Translation – $4 million budget = $120 million in sales
  • Get Out – $4.5 million budget = $255.5 million sales (Shaun Redick)

Note: Revenue from most of Wonderfilm’s current slate will be recorded on the books in 2020 or 2021.

Recent Wonderfilm Releases

  • Aug. 17, 2019: Co-produced with NBC/Universal, “Zombie Tidal Wave” premièred on the SYFY channel to strong ratings.
  • Aug. 29, 2019: “The Fanatic” starring John Travolta opens in U.S. theaters.
  • Sept. 5, 2019: “Tammy’s Always Dying” premiers at Toronto Film Festival.
  • Nov. 8, 2019: “Primal” starring Nicolas Cage opens in U.S. theaters.

Wonderfilm Global Distribution

At the 2019 Cannes Film Festival, Wonderfilm officially launched Wonderfilm Global, a new film, television and media foreign sales/distribution joint venture with 101 Films and Paul McGowan.

Wonderfilm acquired 51% ownership in the joint venture structure and immediately began attaching its own productions to Wonderfilm Global. The joint venture represents a significant opportunity for Wonderfilm, changing how the company does business.

The intention behind Wonderfilm Global is to keep distribution margins in-house that previously went to other companies. Since most Wonderfilm movies are relatively low-risk and easy to sell because they feature desirable cast and genre, third-party distribution companies were previously earning approximately 10%, plus expenses, on Wonderfilm movies without any level of risk. Now, revenue is generated through presales of Wonder?lm projects and, at times, third-party films. The average Wonder?lm movie is pre-sold for $5million, garnering $500,000 to $750,000 per sale as a commission. These commissions now stay in-house with Wonder?lm Global, and the company expects to sell 10 to 12 third-party films between fall 2019 and fall 2020, generating roughly $6 million in commission income.

A further revenue source is generated from theatrical sales through a 50/50 upside split once the minimum sales threshold is met.

Wonder?lm Global has offices in Vancouver, Beverly Hills, London, Ireland, Seoul and China.

Wonderfilm Business Model

Wonderfilm productions are structured to begin generating a return to the company as soon as the camera starts rolling.

Return Before a Film is Delivered: Producer fee line items are included in each production budget. These range from $50,000 to $500,000, depending on the total budget, and are paid to Wonderfilm most commonly on the first day of principle photography.

Distribution: Wonderfilm Global charges sales and distribution fees within each production budget to cover its presale costs.

Note: Wonderfilm’s productions are all structured to minimize risk by matching budget to funds available.

Return After a Film is Delivered: Unsold presale territories are countries or territories left off of a film’s presale list, either for strategic reasons or because the broadcaster/distributor is waiting to see the completed film. These outside-the-budget distribution sales become Wonderfilm profit centers.

Sales overages once contracted presale threshold is surpassed.

The company’s film library grows with each new production, adding to future sales revenue. Depending on the agreement, exploitation rights for future worldwide sales return to Wonderfilm four or seven years after delivery. As of October 2019, Wonderfilm’s growing film library comprises 18 titles for future exploitation.

Note: The nature of the film business is that box office revenue lags production up to a couple of years.

$50 Million Wonderfilm Production Fund (WPF):

Wonderfilm is in the process of raising $50 million to establish a Wonderfilm Production Fund (WPF). WPF is designed to consolidate traditional production financing models into a single diversified, asset-backed debt instrument.

The WPF is a highly specialized investment vehicle with noncorrelated market returns normally reserved for institutional banks and specialty lenders, and it would pay 8% interest directly from each Wonderfilm movie or series budget and not from corporate funds. These same interest payments are already added to each production budget, as the company currently closes a separate financing for every film. The WPF would significantly streamline Wonderfilm’s production rate, adding revenue more quickly and broadening the yearly production slate.

For fund investors, the WPF is a dedicated production-financing vehicle designed to offer a risk-moderated approach to investing in film finance. The managed process provides structure and reassurance that are normally experienced only when working with an institutional lender that has a dedicated staff and resources.

All projects being financed are for Wonderfilm productions, with the fund collateral fully secured by receivables, including presale contracts, government incentives, or a guarantee from Wonderfilm for any unsecured amounts as may be permitted.

Wonderfilm Media Corporation (OTC: WDRFF), closed Tuesday's trading session at $0.094, up 4.4444%, on 274,000 volume with 41 trades. The average volume for the last 3 months is 43,574 and the stock's 52-week low/high is $0.075099997/$0.462000012.

Recent News

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF).

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) was featured today in the 420 with CNW by CannabisNewsWire. Democrats in Congress have abandoned two marijuana proposals that were veteran-based and previously approved by Congress as part of their large-scale defense bill.

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (OTCQB: HTPRF), closed Tuesday's trading session at $0.1537, even for the day, on 250 volume. The average volume for the last 3 months is 4,493 and the stock's 52-week low/high is $0.07/$0.920000016.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $0.70, up 1.4493%, on 4,177 volume with 11 trades. The average volume for the last 3 months is 9,390 and the stock's 52-week low/high is $0.611999988/$4.0300002.

Recent News

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

No Borders (OTC: NBDR) today announced its successful execution of a vendor contract with KB Dental Products of South Korea. According to the update, the distribution and direct supply agreement is for the Kerator, MCT Bio and Maruchi dental and endodontics product lines. KB Dental provides NBDR’s MediDent Supplies division with a high value, diverse line of specialty dental and endodontic products ranging from Endosonic systems and implants to EndosealMTA pastes. To view the full press release, visit http://nnw.fm/9eRmv. Also today, the company was highlighted in a publication from CBDWire, examining how it’s becoming more and more common to run into CBD products. They’re everywhere from gas stations, convenience stores, and pharmacies. The CBD revolution started with last year’s Farm Bill. The legislation declassified industrial hemp as a controlled substance, thus allowing the farming, marketing, and sale of industrial hemp and its extracts.

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed Tuesday's trading session at $0.0128, even for the day, on 141,700 volume with 8 trades. The average volume for the last 3 months is 69,118 and the stock's 52-week low/high is $0.007699999/$0.048799999.

Recent News

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTCQB:SING) was recently featured on KTNV Action News Las Vegas during MJBIZCON 2019. See the full feature release here: http://ibn.fm/8hJx9.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Tuesday's trading session at $0.0095, even for the day, on 1,931,881 volume with 91 trades. The average volume for the last 3 months is 2,823,389 and the stock's 52-week low/high is $0.008299999/$0.028799999.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured promissory note. According to the update, the note’s maturity date was extended from December 31, 2019 to March 31, 2020. To view the full press release, visit http://nnw.fm/wODE0.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $2.87, off by 5.9016%, on 11,732 volume with 101 trades. The average volume for the last 3 months is 41,323 and the stock's 52-week low/high is $2.3499999/$8.50.

Recent News

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) was highlighted today in a report by Livemoney. According to the Marijuana Business Factbook, the cannabis industry could be worth $77 billion by 2022. Analysts at Arcview Market Research and BDS Analytics see worldwide sales of $55 billion by 2024. All as people around the world wake up to the health benefits of cannabis, including the treatment of insomnia, stress and anxiety. On top of that, 14% of Americans are now using products that contain CBD, according to a Gallup poll, as retailers rush to keep up with demand.

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Tuesday's trading session at $2.53, off by 1.1719%, on 2,023,111 volume with 5,878 trades. The average volume for the last 3 months is 2,498,296 and the stock's 52-week low/high is $2.00/$8.43999958.

Recent News

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) was featured today in a publication from HempWireNews, examining how, earlier this year, a New Yorker was arrested and slapped with federal drug trafficking charges after the police intercepted and confiscated what they thought was a shipment of marijuana. Ronen Levy was receiving the shipment of hemp from Vermont on his brother’s behalf, Oren Levy, who owns Green Angel CBD. Acting from a tip from a FedEx driver, New York police arrested him and confiscated 106 pounds of hemp.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Tuesday's trading session at $0.91801, off by 3.3674%, on 113,462 volume with 216 trades. The average volume for the last 3 months is 149,430 and the stock's 52-week low/high is $0.779999971/$4.7800002.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, recently announced its appointment of industry veteran Mark K. Ruport to the position of executive chairman and as a member of its board of directors. The appointment, which took effect December 3, 2019, is expected to play a key role in the company’s ongoing efforts to accelerate growth and increase shareholder value. To view the full press release, visit http://nnw.fm/i9aS0. Also today, NetworkNewsWire released a report on SGLB detailing how the company’s PrintRite3D® software, a proprietary real-time, computer-aided inspection (CAI) technology, represents a seismic shift in the quality-assurance process in the manufacture of 3D-printed metal components, and the entire sector is poised for extraordinary growth.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Tuesday's trading session at $0.9919, off by 1.9862%, on 28,703 volume with 90 trades. The average volume for the last 3 months is 190,118 and the stock's 52-week low/high is $0.451099991/$2.46000003.

Recent News

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) continues to attract top talent in the competitive cannabis space with the recent announcements of several key operational hires. Joining Supreme Cannabis is John Griese as chief operating officer; Dan Sippel as general manager of 7ACRES, the company’s 440,000 square foot cultivation facility; and Sándor Wolkensperg as general manager of Supreme Cannabis Kitchener, the company’s new 107,000 square foot manufacturing and packaging facility.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

  • Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
  • Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
  • Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
  • Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

  • Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
  • Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
  • Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
  • R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Tuesday's trading session at $0.4878, off by 3.5873%, on 324,657 volume with 225 trades. The average volume for the last 3 months is 551,973 and the stock's 52-week low/high is $0.432000011/$1.7888.

Recent News

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) was featured today in the 420 with CNW by CannabisNewsWire. Democrats in Congress have abandoned two marijuana proposals that were veteran-based and previously approved by Congress as part of their large-scale defense bill. The House approved its version of the National Defense Authorization Act (NDAA) this summer. The legislation had several changes that would prevent the United States Department of Veteran Affairs from denying the veterans’ home loans applications due to their employment status in the legal marijuana sector.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Tuesday's trading session at $0.372396, off by 4.5138%, on 91,837 volume with 47 trades. The average volume for the last 3 months is 96,935 and the stock's 52-week low/high is $0.354999989/$1.6875.

Recent News

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

Cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC), a Delaware-registered, fully reporting company, has applied for what would be its fifth patent even as laboratory results indicate its revolutionary Hemp You Can Feel™ brand technology has exceeded expectations when it comes to infusing beverages, powders and liquid concentrates to such a degree that all hemp extracts and major cannabinoids are undetectable. Also today, CannabisNewsWire released a report on the company detailing the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. During the interview, Cannabis Global Chairman and CEO Arman Tabatabaei discussed the Company’s strategy to take advantage of opportunities in the cannabis industry while avoiding overcrowded market niches. To listen to the interview, visit http://cnw.fm/HO9Cu. To view the full press release, visit http://cnw.fm/K9Fxi. Additionally, the company was highlighted in a publication from CBDWire. It’s becoming more and more common to run into CBD products. They’re everywhere from gas stations, convenience stores, and pharmacies. The CBD revolution started with last year’s Farm Bill. The legislation declassified industrial hemp as a controlled substance, thus allowing the farming, marketing, and sale of industrial hemp and its extracts.

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Tuesday's trading session at $0.35, off by 2.7778%, on 10,706 volume with 13 trades. The average volume for the last 3 months is 12,514 and the stock's 52-week low/high is $0.075000002/$3.00.

Recent News

OriginClear (OTC: OCLN)

The QualityStocks Daily Newsletter would like to spotlight OriginClear (OTC: OCLN).

Spain’s Depuporc, a company specifically focused on wastewater treatment on hog farms, unveiled an integrated manure-treatment system using OriginClear Inc. (OTC: OCLN)technology. The demonstration system showcases the processing of 30 metric tons per day with client-validation reduction of contaminants for pig farmers. OLCN technology poses major disruptive potential for the animal wastewater treatment sector. The full Depuporc system presentation video can be viewed at http://nnw.fm/9RdqA.

OriginClear (OTC: OCLN) leads the self-reliant water revolution, deploying advanced technologies at the point of use, with modular, prefabricated systems that create durable assets and water independence for industry, commerce and agriculture.

Failing infrastructure and the rising cost of water are driving businesses to treat their own water. OriginClear leads this megatrend with on-premise systems enabling very high purification and recycling levels that centralized systems cannot achieve.

Systems installed at the point of use become productive assets for businesses that also increase property values. And OriginClear helps corporations improve their environmental, social and governance (ESG) standings with world-class water management.

Operations & Markets

OriginClear leads a new generation of water companies that focus on meeting the needs of businesses looking for compact, advanced technologies that can be shipped to and installed at the point of use. The company manufactures and distributes its professional-grade water treatment and conveyance products to commercial and industrial properties, fielding both direct and indirect sales channels to reach end-market clients such as hotels and resorts, real estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouse, oil and gas producers, and medical and pharmaceutical facilities.

From its Texas-based factory, OriginClear designs and prefabricates an entire line of plug-n-play containerized units called Modular Water Systems™ that enable water purification, recycling and wastewater management.


Industrial Pretreatment Waste Water Treatment Plant (WWTP) designed by Daniel M. Early, using reinforced thermoplastic modules.

These onsite modular products provide clients with water independence through ownership and operational control over water quality, enabling them to increase productivity while reducing environmental, health and safety risks from pollution, contamination and corrosion. Modular water products are trusted to balance performance with cost-effectiveness, enabling business users to go well beyond municipal standards for water quality, therefore achieving high levels of satisfaction for their own customers, and improved sustainability for their properties.

OriginClear’s water treatment equipment can boost real estate asset value as a fundamental capital improvement, combined with long-lasting water savings for the corporate bottom line.

Product Portfolio

OriginClear groups its products into three main categories:

  1. Water Treatment: achieving high grade purification.
  2. Water Conveyance: water transportation and pumping.
  3. Advanced Technologies: commercialization of innovative technologies.

OriginClear’s complete line of compact, on-site, point-of-use products include: advanced purification systems that are skid, rack-mounted and containerized for reverse osmosis, ultrafiltration, media filtration, disinfection, water softening, ion exchange and electrodeionization (EDI), combined as needed in small to medium commercial and industrial applications, and custom-build projects. Water conveyance products include pump and lifting stations, modular storage tanks, and control monitoring panels.

OriginClear’s line of modular water products and systems is key to the self-reliant water treatment revolution as they create “instant infrastructure” – fully engineered, prefabricated and prepackaged systems that use durable, sophisticated materials. The units are available in standard capacities for onsite closed-loop systems at commercial business locations.

The company’s rugged wastewater treatment plants, highly reliable pump stations, and premium water purification units typically offer 25 percent lower initial costs over conventional systems, with greater quality and full connectivity. These pump stations and wastewater treatment products utilize high density thermo-plastics (HDPE) and proprietary, innovative prefabrication methods and materials that deliver the longest life and strongest products.

Breakthrough Technologies

OriginClear has a long history of innovation through its OriginClear Technologies division, which is responsible for identifying leading-edge technologies to solve today’s toughest challenges. These advanced technologies are the centerpiece of the division’s international licensee network. The technologies are developed in OriginClear Technologies, and licensees integrate them into their own products.

Electro Water Separation™ (EWS) and Advanced Oxidation (AOx™) are the principal, well-proven technologies.

EWS is OriginClear’s breakthrough water cleanup technology which utilizes a catalytic process to concentrate and eliminate suspended solids in the worst commercial and industrial wastewater.

AOx is OriginClear’s proprietary advanced oxidation technology which generates a dense cloud of ozone, hydrogen peroxide and hydroxyl radicals, dramatically reducing or eliminating dissolved organic microtoxins, including bacteria and viruses, hormones, drugs, pesticides such as Roundup, and synthetics. AOx has also been shown to effectively reduce harmful chemicals such as ammonia and hydrogen sulfide – the “rotten egg” smell in crude oil that reduces its value.

Through international licensing and partnerships, OriginClear’s advanced technologies are being adopted to treat tough water problems in East and South Asia, Europe and the Middle East, and North America.

Market Opportunity

In just 10 years, the global water services market has doubled into a trillion-dollar industry, driven by improper sanitation and water scarcity. Only 20 percent of all sewage and only 30 percent of all industrial waste are ever treated. Additionally, water leakage results in the loss of 35 percent of all clean water across the planet; reducing that percentage by half would provide clean water for 100 million people. This is a situation of great danger, but also great potential.

The statistics demonstrate that we can no longer rely on the efficiencies of giant, centralized water utilities to meet these challenges. An increasing number of businesses are starting to take notice, instead conducting their own water treatment and recycling. Whether by choice or out of necessity, those businesses that do invest in onsite water systems get a tangible asset on their business and real estate, and can enjoy better water quality at a lower cost.

Out of the public’s eye and with OriginClear’s help, a growing number of self-reliant businesses are building Decentralized Water Wealth™ for themselves while also helping their community. They know that environmental, social and governance (ESG) investing guidelines, which represent $22 trillion of assets under management around the world, specifically note the key indicator of how well corporations manage their water.


10,000 Gallon per Day Industrial Membrane Bioreactor Waste Water Treatment Plant designed by Daniel M. Early, PE, using long-lived Structural Reinforced ThermoPlastic (SRTP)

OriginClear is a key enabler of ESG water management for corporations that are increasingly responsible for what was once delegated to central utilities. For example, when a corporation manages its own water, and uses OriginClear’s proprietary hybrid treatment methods, it can significantly reduce both water use and nutrient footprints (carbon, nitrogen, and phosphorus) in one compact package.

These hybrid processes feature advanced blackwater treatment with advanced clean water processing. They can convert toxic nutrients to less harmful compounds, and even capture them for beneficial reuse purposes, as shown in OriginClear’s recent case study.

Revenue Growth through Synergy

Since OriginClear acquired it in 2015, Progressive Water Treatment has generated steady revenues in the range of a million dollars a quarter. It is now the Fabrication and Manufacturing Division for the whole company. The team at Modular Water Systems, headed by Chief Engineer Daniel M. Early, is responsible for overall design and high-level engineering. It relies on the Fabrication and Manufacturing Division to add incremental revenue for its modular product line, without requiring large increases in personnel.

OriginClear believes that these two business units can develop growing revenues through synergy and ultimately help achieve overall profitability. OriginClear also seeks to acquire profitable water companies that can complement the synergy of its existing units and accelerate both revenues and profitability. However, acquisitions are neither guaranteed, nor essential to OriginClear’s continued growth.

 

Leadership

OriginClear’s management team brings strong leadership and a background in managing business operations, sales, technologies, and finance. The team combines idealism with solid commercial skills, achieving a triple bottom line of environmental, social and financial gain.

Riggs Eckelberry – Chairman, CEO and Co-founder
Riggs Eckelberry is a veteran technology manager who led companies to multiple exits during the high-tech boom of the 90s and early 2000s. Eckelberry came to the water industry from a quarter century in high technology, specializing in commercializing breakthrough technologies. During the dotcom boom, he worked on a series of tech successes, such as Quarterdeck’s CleanSweep; security software vendor Panda Software; and the sale of companies to EarthWeb, BeFree, and BellSouth. Just prior to founding what is now OriginClear, he helped drive security software company CyberDefender to an IPO on the Nasdaq as its president and chief operating officer.

Thomas Marchesello – Chief Operating Officer
Thomas Marchesello is a business operations and technology executive with over 20 years’ experience in manufacturing and distribution of products and services. He has 12 years in private equity M&A, doing buyside acquisitions of small to midsize corporations. He has over 10 years advising innovative corporations on ESG strategy and speaks often about industry trends. He began his career in the U.S. Air Force, Space Command Headquarters for environmental sciences. He has held key roles for Fortune 500 companies such as Sony, Thompson Reuters, Morgan Stanley, and Chicago Mercantile Exchange.

Daniel M. Early, PE – Senior Engineer
For the past 25 years, Dan Early has worked as an engineered products development specialist with very strong understanding of the complex and interconnected disciplines, economies, and governmental regulation needed to develop and sustain modern civil infrastructure systems that reflect a balance of environmental stewardship, social expectations, and cultural requirements. Since 2010, Early has specialized in the research, development, and deployment of next generation water infrastructure technologies using heavy plastic manufacturing. His initiatives and innovations anchor Modular Water Systems’ product line.

Marc Stevens – Director of Fabrication and Manufacturing
Marc Stevens brings nearly 40 years of experience to OriginClear’s manufacturing team. His experience in mechanical design, equipment fabrication, installation and a wide range of projects led to his founding what is now OriginClear’s Fabrication and Manufacturing Division. He supervises the design, building and installation of customized, large-scale water treatment systems, including purification technologies for process waters for boilers and cooling towers, drinking water and various industrial waste water applications. Stevens leads the team that also manufactures OriginClear’s standardized Modular Water Systems.

OriginClear (OCLN), closed Tuesday's trading session at $0.25, off by 19.3548%, on 146,763 volume with 49 trades. The average volume for the last 3 months is 33,924 and the stock's 52-week low/high is $0.100000001/$5.80000019.

Recent News

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, today released findings from a new Harris Poll online survey, conducted on their behalf among over 2,000 U.S. adults, on consumer night snacking and sleep quality. 83% of U.S. consumers report snacking at least one night a week, and 20% of consumers report snacking every night. The most popular nighttime snack choices overall are salty snacks (such as chips, popcorn, and pretzels – 84%), baked goods (such as cookies, cake, donuts – 80%), candy (chocolate, gummies, hard candies – 76%), and ice cream (75%).

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Tuesday's trading session at $0.240002, off by 2.04%, on 76,990 volume with 21 trades. The average volume for the last 3 months is 149,368 and the stock's 52-week low/high is $0.165999993/$0.920000016.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.